Doctor

Advice and explanations about dementia testing, diagnosis, medical practitioners and medications.

NMDA receptor antagonist

NMDA receptor antagonist

by MATT KWONG
Contributor

What is an example of an NMDA receptor antagonist?

The only drug in this newer class of Alzheimer’s disease drugs is Memantine, which is commonly marketed as Namenda or Ebixa.

The FDA approved its use in 2003. The drug comes in pill form, to be taken twice a day.

How NMDA receptor antagonist works:

Memantine works by blocking a receptor in the brain called glutamate, thereby guarding against brain cell death.

Neurologists blame overstimulation of glutamate receptors for accelerating that damage to cell structures.

While the three cholinesterase inhibitor drugs are meant to “enhance what we believe is good brain signalling, Namenda is meant to decrease what we think is bad brain signalling,” said Klunk.

For that reason, he said, Alzheimer’s patients are often prescribed a mix of both types of drug .

“Probably the most common thing I see is people coming into our clinic with Aricept and Namenda together,” he said.

The NMDA receptor antagonist is generally prescribed for “moderate to severe” Alzheimer’s.

Dementia Drugs: What You Need To Know

How Well Do These Drugs Work?

Examples of cholinesterase inhibitors

What About Alternative Treatments?

 

Matt Kwong is a writer based in Atlanta, Georgia, and Toronto, Ontario



About the author

Matt Kwong

Read All Articles by Matt Read More Read Less

You might also enjoy:

Video conferencing a dementia savior

Can video conferencing help people with dementia in rural communities? The answers may lie in two research…

Doctors don’t know everything

Unless you share everything. Waiting rooms in doctor’s offices across North America are filled with…

The Silence of Doctors Around Dementia

“A fate worse than death,” my colleague muttered to me as we examined an elderly man admitted to…

Promising Eye Test in Identifying AD

In January 2014, Cognoptix announced the strong results of a multi-site clinical trial of its SAPPHIRE…

comments powered by Disqus